Diabetic Foot Ulcers – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Diabetic Foot Ulcers – Pipeline Review, H2 2019’, provides an overview of the Diabetic Foot Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers

– The report reviews pipeline therapeutics for Diabetic Foot Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Diabetic Foot Ulcers therapeutics and enlists all their major and minor projects

– The report assesses Diabetic Foot Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Alan Laboratories Inc

Anterogen Co Ltd

Aposcience AG

Aprogen Inc

APstem Therapeutics Inc

AptaBio Therapeutics Inc

Aurealis Therapeutics AG

Biofilm Pharma

Biotherapy Services Ltd

Blue Blood Biotech Corp

Canton Biotechnologies Inc

CardioVascular BioTherapeutics Inc

Celularity Inc

Chiesi Farmaceutici SpA

CSA Biotechnologies LLC

Cynata Therapeutics Ltd

CytoTools AG

Destiny Pharma Plc

Energenesis Biomedical Co Ltd

EyeGene Inc

FirstString Research Inc

Genentech Inc

Helixmith Co Ltd

Hoth Therapeutics Inc

Human Stem Cells Institute

Imstem Biotechnology Inc

Lakewood-Amedex Inc

Liminal BioSciences Inc

Mallinckrodt Plc

MangoGen Pharma Inc

MediWound Ltd

Mirae Cell Bio Co Ltd

NovaLead Pharma Pvt Ltd

OliX Pharmaceuticals Inc

Orbsen Therapeutics Ltd

Pherecydes Pharma SA

Promore Pharma AB

QBiotics Ltd

Remedor Biomed Ltd

RHEACELL GmbH & Co KG

Riptide Bioscience Inc

Serodus ASA

Shionogi & Co Ltd

Sinobioway Biomedical Co Ltd

Stempeutics Research Pvt Ltd

Suzhou Kintor Pharmaceutical Inc

TechnoPhage SA

TGV-Inhalonix Inc

Topadur Pharma AG

Transwell Biotech Co Ltd

USV Pvt Ltd

Vasomune Inc

Xenexus Pharmaceuticals Pty Ltd

ZZ Biotech LLC”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Foot Ulcers - Overview 6

Diabetic Foot Ulcers - Therapeutics Development 7

Diabetic Foot Ulcers - Therapeutics Assessment 17

Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 25

Diabetic Foot Ulcers - Drug Profiles 37

Diabetic Foot Ulcers - Dormant Projects 118

Diabetic Foot Ulcers - Discontinued Products 122

Diabetic Foot Ulcers - Product Development Milestones 123

Appendix 132

List of Tables

“List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Diabetic Foot Ulcers – Pipeline by Alan Laboratories Inc, H2 2019

Diabetic Foot Ulcers – Pipeline by Anterogen Co Ltd, H2 2019

Diabetic Foot Ulcers – Dormant Projects, H2 2019

Diabetic Foot Ulcers – Dormant Projects, H2 2019 (Contd..1), H2 2019

Diabetic Foot Ulcers – Dormant Projects, H2 2019 (Contd..2), H2 2019

Diabetic Foot Ulcers – Dormant Projects, H2 2019 (Contd..3), H2 2019

Diabetic Foot Ulcers – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Diabetic Foot Ulcers, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports